[go: up one dir, main page]

WO2016073879A3 - Transforming growth factor-related antibodies and uses thereof - Google Patents

Transforming growth factor-related antibodies and uses thereof Download PDF

Info

Publication number
WO2016073879A3
WO2016073879A3 PCT/US2015/059515 US2015059515W WO2016073879A3 WO 2016073879 A3 WO2016073879 A3 WO 2016073879A3 US 2015059515 W US2015059515 W US 2015059515W WO 2016073879 A3 WO2016073879 A3 WO 2016073879A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
antibodies
proteins
growth factor
family member
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/059515
Other languages
French (fr)
Other versions
WO2016073879A2 (en
Inventor
Gregory J. Carven
Justin W. JACKSON
Michelle STRAUB
Dong Yun Lee
William K. MCCONAUGHY
Jared J. SHEEHAN
Katherine Jane Turner
Nagesh K. Mahanthappa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scholar Rock Inc
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of WO2016073879A2 publication Critical patent/WO2016073879A2/en
Publication of WO2016073879A3 publication Critical patent/WO2016073879A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are proteins, antibodies, assays, compositions and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins. Aspects of the disclosure relate to a recognition that in some embodiments antibodies have selected binding profiles to TGF-β family member proteins and/or forms thereof. In some embodiments antibodies with selected binding profiles specifically bind to different forms of TGF-β family member proteins. For example, antibodies provided herein specifically bind to one or more of a pro-form, a latent-form, a primed-form, and/or a matureform of a TGF-β family member protein, such as proMyostatin, latent Myostatin, primed Myostatin and/or mature Myostatin.
PCT/US2015/059515 2014-11-06 2015-11-06 Transforming growth factor-related antibodies and uses thereof Ceased WO2016073879A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462076230P 2014-11-06 2014-11-06
US62/076,230 2014-11-06
US201562100361P 2015-01-06 2015-01-06
US62/100,361 2015-01-06
US201562187348P 2015-07-01 2015-07-01
US62/187,348 2015-07-01

Publications (2)

Publication Number Publication Date
WO2016073879A2 WO2016073879A2 (en) 2016-05-12
WO2016073879A3 true WO2016073879A3 (en) 2016-06-23

Family

ID=55910042

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2015/059515 Ceased WO2016073879A2 (en) 2014-11-06 2015-11-06 Transforming growth factor-related antibodies and uses thereof
PCT/US2015/059557 Ceased WO2016073906A2 (en) 2014-11-06 2015-11-06 Transforming growth factor-related immunoassays

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2015/059557 Ceased WO2016073906A2 (en) 2014-11-06 2015-11-06 Transforming growth factor-related immunoassays

Country Status (1)

Country Link
WO (2) WO2016073879A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
PT2708559T (en) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
MX365235B (en) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly.
TWI855488B (en) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
JP6706617B2 (en) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Anti-pro/latent-myostatin antibodies and uses thereof
MX2017005774A (en) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use.
SG11201706014PA (en) 2015-02-05 2017-08-30 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
JP2018527903A (en) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． GDF11 binding protein and use thereof
RS62330B1 (en) 2015-09-15 2021-10-29 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof
CA3002422C (en) * 2015-12-18 2024-04-16 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP7141336B2 (en) 2015-12-25 2022-09-22 中外製薬株式会社 Anti-myostatin antibodies and methods of use
US10287345B2 (en) 2016-01-08 2019-05-14 Scholar Rock, Inc. Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
KR20210082548A (en) 2016-06-13 2021-07-05 스칼러 락, 인크. Use of myostatin inhibitors and combination therapies
CN109311969B (en) * 2016-06-17 2022-09-27 中外制药株式会社 Anti-myostatin antibodies and methods of use
CA3029977A1 (en) 2016-07-06 2018-01-11 Celgene Corporation Antibodies with low immunogenicity and uses thereof
CN109689689B (en) * 2016-07-22 2022-12-06 丹娜法伯癌症研究所公司 Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
KR102538749B1 (en) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Composition for prophylaxis or treatment of il-8 related diseases
US11111313B2 (en) * 2016-09-20 2021-09-07 WuXi Biologics Ireland Limited Anti-PCSK9 antibodies
CN107840893B (en) * 2016-09-20 2022-02-25 信立泰(成都)生物技术有限公司 Novel anti-PCSK9 antibody
RU2770590C2 (en) * 2016-10-30 2022-04-18 Шанхай Хенлиус Байотек, Инк. Antibodies against pd-l1 and their options
PT3565592T (en) * 2017-01-06 2023-05-31 Scholar Rock Inc Methods for treating metabolic diseases by inhibiting myostatin activation
SI3565592T1 (en) 2017-01-06 2023-05-31 Scholar Rock, Inc. Treating metabolic diseases by inhibiting myostatin activation
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
WO2019055399A1 (en) * 2017-09-12 2019-03-21 Igc Bio, Inc. Anti-vegf antibody
CN113372441B (en) * 2018-04-04 2023-03-10 中国科学院微生物研究所 A highly sensitive yellow fever virus human monoclonal antibody and its application
WO2019210144A1 (en) * 2018-04-27 2019-10-31 Vanderbilt University Broadly neutralizing antibodies against hepatitis c virus
AU2019299110B2 (en) * 2018-07-03 2025-07-17 Catalent Pharma Solutions, Llc Multifunctional protein molecules comprising decorin and use thereof
AU2019301633A1 (en) 2018-07-09 2021-01-28 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
WO2020264410A1 (en) * 2019-06-26 2020-12-30 Sensor-Kinesis Corporation Troponin t binding agents and uses thereof
TWI859420B (en) 2020-02-26 2024-10-21 美商維爾生物科技股份有限公司 Antibodies against sars-cov-2 and methods of using the same
CN111662379B (en) * 2020-05-09 2021-03-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) Antibody for resisting novel coronavirus, preparation method and application
JP2023549854A (en) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド Liver-specific Wnt signal enhancing molecules and their uses
EP4259201A4 (en) * 2020-12-08 2025-03-19 Memorial Sloan Kettering Cancer Center Antibodies against galectin-3 and methods of using the same
US20250179196A1 (en) * 2021-07-30 2025-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
CN115322257B (en) * 2021-08-16 2023-05-30 上海优替济生生物医药有限公司 BCMA targeting antibody, chimeric antigen receptor and application thereof
EP4147716A1 (en) * 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
WO2023086336A2 (en) * 2021-11-09 2023-05-19 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Molecules that bind to prostate specific membrane antigen (psma) polypeptides
KR20250122524A (en) 2022-12-22 2025-08-13 스칼러 락, 인크. A selective and potent inhibitory antibody for myostatin activation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096506A (en) * 1993-03-19 2000-08-01 The Johns Hopkins University School Of Medicine Antibodies specific for growth differentiation factor-8 and methods of using same
US20110239317A1 (en) * 1997-02-05 2011-09-29 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US20130209489A1 (en) * 2010-08-16 2013-08-15 Huiquan Han Antibodies That Bind Myostatin, Compositions And Methods
US20140023638A1 (en) * 2007-11-01 2014-01-23 Pfizer Inc. Antibody to gdf8 and uses thereof
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096506A (en) * 1993-03-19 2000-08-01 The Johns Hopkins University School Of Medicine Antibodies specific for growth differentiation factor-8 and methods of using same
US20110239317A1 (en) * 1997-02-05 2011-09-29 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US20140023638A1 (en) * 2007-11-01 2014-01-23 Pfizer Inc. Antibody to gdf8 and uses thereof
US20130209489A1 (en) * 2010-08-16 2013-08-15 Huiquan Han Antibodies That Bind Myostatin, Compositions And Methods
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Also Published As

Publication number Publication date
WO2016073906A3 (en) 2016-07-21
WO2016073879A2 (en) 2016-05-12
WO2016073906A2 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
WO2016073879A3 (en) Transforming growth factor-related antibodies and uses thereof
WO2015171691A3 (en) Compositions and methods for growth factor modulation
WO2014182676A3 (en) Compositions and methods for growth factor modulation
WO2017172260A8 (en) Binding proteins and methods of use thereof
WO2015112886A3 (en) Binding proteins and methods of use thereof
MX2022006759A (en) ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME.
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
MX2022012749A (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies.
SG10201909716RA (en) Modified j-chain
MX2022006461A (en) Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof.
WO2017120523A3 (en) Anti-pro/latent myostatin antibodies and methods of use thereof
HK1251158A1 (en) Pd-1 binding proteins and methods of use thereof
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
WO2014177459A3 (en) Fc-receptor binding modified asymmetric antibodies and methods of use
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
MX382518B (en) CYTOMEGALOVIRUS ANTIGENS AND THEIR USE.
WO2016073789A3 (en) Anti-fgfr2/3 antibodies and methods using same
EP3155018A4 (en) Constant region antibody fusion proteins and compositions thereof
WO2016205531A3 (en) Anti-her2 antibodies and methods of use
WO2016048188A8 (en) High affinity and aggregatively stable antibodies on the basis of variable domains vl and a derivative vhh
WO2017087912A3 (en) Ratiometric biosensors and non-geometrically modulated fret
WO2015143406A3 (en) Vl antigen binding proteins exhibiting distinct binding characteristics
WO2017021539A3 (en) Novel anti-human gpvi antibodies and uses thereof
MX2022009915A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof.
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15858050

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15858050

Country of ref document: EP

Kind code of ref document: A2